Invokana Lawsuit Plaintiffs See Increased Adverse Event Reports And Label Changes For Drug

March 29, 2016 – – TheProductLawyers.com reports on the issuance of a public safety announcement regarding new-generation drug Invokana by the U.S. Food and Drug Administration (FDA) on December 4, 2015. The agency’s statement discussed new requirements for the warning label of the type-2 diabetes drug, which are to be altered by the product’s manufacturer, Johnson & Johnson subdivision Janssen Pharmaceuticals.

The decision to make this public statement followed the receipt of a large number of adverse event reports by the agency. These adverse event reports discussed health problems which were appearing among patients taking Invokana or similar SGLT2 class inhibitor drugs. The FDA’s statement specifically notes a potentially life-threatening condition called diabetic ketoacidosis. This condition develops when the body’s bloodstream begins to contain a surplus of toxic acid or ketones. Because this condition can cause patients to enter comatose states or pass away, it is being taken very seriously. The FDA has indicated that patients currently using SGLT2 class inhibitor drugs should carefully look for signs of developing ketoacidosis, which may include vomiting or nausea, frequent urges to urinate, excess fatigue, abdominal pain, and difficulty breathing, among other things.

The adverse event report links have brought concern to the public, especially type-2 diabetes patients currently depending upon the drug. The FDA further discussed their findings, noting that, “All patients required hospitalization or treatment in an emergency department. In many cases, ketoacidosis was not immediately recognized because the blood glucose levels were below those typically expected for diabetic ketoacidosis. As a result, treatment of the ketoacidosis was delayed in some cases.”

The attorneys of Banville Law are dedicated to informing the public about the latest important updates concerning Invokana and similar drugs, and, therefore, sponsor TheProductLawyers.com as an online resource. They are also now assisting any patients who have used Invokana or other SGLT2-class inhibitor drugs and who have suffered from health problems that they believe were caused by their use of these drugs. The attorneys of Banville Law want to ensure that these individuals are provided with an opportunity to fully investigate their legal rights in the matter, as they may be entitled to substantial compensation. To help patients wishing to look further into legal action, Banville Law attorneys are also offering complimentary legal consultations at this time.

To request additional Invokana lawsuit information, or to ask questions, please contact the attorneys of Banville Law by calling 877-671-6480.

###

Contact TheProductLawyers.com:

Banville Law
877-671-6480
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60008957